Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display

Summary

Clotting factor VIII (fVIII)-inhibitory antibodies represent a major problem in the treatment of haemophilia A. To understand the inactivation mechanisms and to pave the way towards modifications of recombinant clotting factors that reduce their immunogenicity, the exact localization of immunodominant epitopes is required. Here, a random peptide phage display library was employed to identify epitopes of polyclonal fVIII antibodies isolated from patient’s plasma by affinity chromatography. FVIIIbinding specificity and inhibitory activity of the isolated fVIII antibodies were confirmed by ELISA and Bethesda assays. Phage selection on the individual samples yielded several phages which were displaced from binding to the respective antibody preparation by fVIII. Their homology with amino acid motifs of human fVIII and immunoprecipitation results with radioactively labelled fVIII fragments suggested putative epitopes in the A1, A2 and C1 domains of fVIII for one and in the C2 domain for another patient. Synthetic peptides corresponding to the A2, C1 and C2 domain epitopes blocked antibody binding to fVIII and partially neutralized the inhibitory activity of the respective plasma in Bethesda assays. These results provide the proof of principle that random peptide libraries can be used for the mapping of epitopes in a polyclonal antibody preparation.

Keywords

Haemophilia - inhibitor - polyclonal antibodies - epitope mapping - phage display

• References

• 1 Ehrenforth S, Kreuz W, Scharrer I. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
• 2 Rothschild C, Laurian Y, Satre EP. et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-83.
• 3 Gruppo R, Bray GL, Schroth P. et al. for the Recombinate PUP Study Group. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): a 6.5 year update. Thromb Haemost. 1997 162. Suppl.: PD-663.
• 4 Lusher JM, Shapiro A, Gruppo R. et al. the ReFacto PUP Study Group. Safety and efficacy in previously untreated patients (PUPs) treated exclusively with B-domain deleted factor VIII (BDD rfVIII). Thromb Haemost 2001; Congress Suppl. 2558.
• 5 Lacroix-Desmazes S, Misra N, Bayry J. et al. Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. Haemophilia 2002; 08: 273-9.
• 6 Saenko EL, Ananyeva NM, Tuddenham EG. et al. Factor VIII - novel insights into form and function. Br J Haematol 2002; 119: 323-31.
• 7 Pittman DD, Alderman EM, Tomkinson KN. et al. Biochemical, immunological, and in vivo functional characterization of B-domaindeleted factor VIII. Blood 1993; 81: 2925-35.
• 8 Scandella DH, Nakai H, Felch M. et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res 2001; 101: 377-85.
• 9 Scandella D, Gilbert GE, Shima M. et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-9.
• 10 Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang 1996; 70 (Suppl. 01) 9-14.
• 11 Healey JF, Lubin IM, Nakai H. et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-9.
• 12 Saenko EL, Ananyeva NM, Kouiavskaia DV. et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002; 08: 1-11.
• 13 Fulcher CA, de Graaf SMahoney, Roberts JR. et al. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-32.
• 14 Ware J, MacDonald MJ, Lo M. et al. Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. Blood Coagul Fibrinolysis 1992; 03: 703-16.
• 15 Scandella D, DeGraaf SMahoney, Mattingly M. et al. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6.
• 16 Palmer DS, Dudani AK, Drouin J. et al. Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays. Vox Sang 1997; 72: 148-61.
• 17 Azzazy HM, Highsmith Jr WE. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002; 35: 425-45.
• 18 Verbruggen B, Novakova I, Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
• 19 Jost PJ, Harbottle RP, Knight A. et al. A novel peptide, THALWHT, for the targeting of human airway epithelia. FEBS Lett 2001; 489: 263-9.
• 20 Villard S, Piquer D, Raut S. et al. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002; 277: 27232-9.
• 21 Stoilova-McPhie S, Villoutreix BO, Mertens K. et al. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
• 22 Villard S, Lacroix-Desmazes S, Kieber-Emmons T. et al. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood 2003; 102: 949-52.